- Home
- EPOW vs AEON Comparison
EPOW vs AEON Comparison
Compare EPOW & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPOW | AEON |
|---|---|---|
| Founded | 2014 | N/A |
| Country | China | United States |
| Employees | N/A | 5 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 26.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | EPOW | AEON |
|---|---|---|
| Price | $0.84 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | ★ 162.5K | 74.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.38 |
| 52 Week High | $1.86 | $1.45 |
Technical Indicators
Market Signals| Indicator | EPOW | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 38.89 |
| Support Level | $0.74 | $0.87 |
| Resistance Level | $1.05 | $1.12 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 28.38 | 10.00 |
Price Performance
Historical ComparisonAbout EPOW Sunrise New Energy Co. Ltd
E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. The company operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, it also operates a knowledge sharing platform business.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.